- Home
- NHI vs RNA Comparison
NHI vs RNA Comparison
Compare NHI & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NHI
- RNA
- Stock Information
- Founded
- NHI 1991
- RNA 2012
- Country
- NHI United States
- RNA United States
- Employees
- NHI N/A
- RNA N/A
- Industry
- NHI Real Estate Investment Trusts
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- NHI Real Estate
- RNA Health Care
- Exchange
- NHI Nasdaq
- RNA Nasdaq
- Market Cap
- NHI 3.5B
- RNA 3.4B
- IPO Year
- NHI 1991
- RNA 2020
- Fundamental
- Price
- NHI $72.47
- RNA $30.98
- Analyst Decision
- NHI Buy
- RNA Strong Buy
- Analyst Count
- NHI 5
- RNA 12
- Target Price
- NHI $82.20
- RNA $67.92
- AVG Volume (30 Days)
- NHI 264.5K
- RNA 1.4M
- Earning Date
- NHI 05-05-2025
- RNA 05-08-2025
- Dividend Yield
- NHI 4.96%
- RNA N/A
- EPS Growth
- NHI 3.74
- RNA N/A
- EPS
- NHI 3.16
- RNA N/A
- Revenue
- NHI $343,615,000.00
- RNA $8,927,000.00
- Revenue This Year
- NHI $6.77
- RNA N/A
- Revenue Next Year
- NHI $11.76
- RNA $148.12
- P/E Ratio
- NHI $22.97
- RNA N/A
- Revenue Growth
- NHI 7.49
- RNA N/A
- 52 Week Low
- NHI $64.00
- RNA $21.51
- 52 Week High
- NHI $86.13
- RNA $56.00
- Technical
- Relative Strength Index (RSI)
- NHI 42.08
- RNA 53.85
- Support Level
- NHI $71.75
- RNA $30.00
- Resistance Level
- NHI $73.26
- RNA $32.09
- Average True Range (ATR)
- NHI 1.39
- RNA 1.79
- MACD
- NHI -0.30
- RNA 0.13
- Stochastic Oscillator
- NHI 16.60
- RNA 75.00
About NHI National Health Investors Inc.
National Health Investors Inc is a housing and medical facility REIT. The company operates through two reportable segments, i.e., Real Estate Investments and Senior Housing Operating Portfolio (SHOP). The Real Estate Investments segment, which generates maximum revenue, consists of real estate investments and leases, mortgages, and other notes receivables in independent living facilities, assisted living facilities, entrance fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment is comprised of two ventures that own the operations of independent living facilities. The company's revenues are derived in the form of rental income, mortgage and other notes receivable interest income, and resident fees and services.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.